Alison R. Sehgal
Experienced in Essential Thrombocythemia

Dr. Alison R. Sehgal

Hematology Oncology
UPMC
UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
On Staff At
Accepting New Patients
Offers Telehealth

Experienced in Essential Thrombocythemia
UPMC
UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alison Sehgal, MD, is an assistant professor of medicine at the University of Pittsburgh School of Medicine, and a hematologist/medical oncologist specializing in allogeneic and autologous stem cell transplant, lymphoma, leukemia, and multiple myeloma. Dr. Sehgal is conducting research in stem cell transplant and drug development in hematologic malignancies.

Dr. Sehgal is rated as an Experienced provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 42 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Duke University School Of Medicine
Residency
University of Pennsylvania Health System
Specialties
Hematology Oncology
Licenses
Internal Medicine in PA
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
University of Pennsylvania Health System
Hospital Affiliations
Magee Womens Hospital Of Upmc Health System
Upmc Presbyterian Shadyside
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, Pittsburgh, PA 15232
Call: 412-946-2861

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD
A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cyclophosphamide, Fludarabine, Methotrexate, Mycophenolate Mofetil, Tacrolimus, Thiotepa
Study Phase: Phase 2
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug, Biological
Study Drugs: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Study Phase: Phase 2
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Biological
Study Drug: JCAR017 (Lisocabtagene Maraleucel) 
Study Phase: Phase 1
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Biological
Study Drug: Lisocabtagene maraleucel
Study Phase: Phase 2
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With Acute Myeloid Leukemia (AML) Who Are Not Transplantation Candidates
A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With Acute Myeloid Leukemia (AML) Who Are Not Transplantation Candidates
Enrollment Status: Completed
Publish Date: August 10, 2021
Intervention Type: Drug
Study Phase: Phase 2
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Enrollment Status: Completed
Publish Date: October 15, 2019
Intervention Type: Drug, Other, Radiation
Study Phase: Phase 1
View 6 Less Clinical Trials

42 Total Publications

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 16, 2025
View All 42 Publications
Similar Doctors
Kevin M. Kane
Distinguished in Essential Thrombocythemia
Dr. Kevin M. Kane
Hematology Oncology
Distinguished in Essential Thrombocythemia
Dr. Kevin M. Kane
Hematology Oncology

UPMC Hillman Cancer Center

1500 5th Avenue, 
Mckeesport, PA 
 (8.3 miles away)
412-664-2607
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Kane has practiced for more than 20 years and is board certified in Medical Oncology. He received his medical degree from Ohio State University School of Medicine. He completed his residency training in Hematology/Oncology at the University of Pittsburgh School of Medicine. Dr. Kane is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Non-Hodgkin Lymphoma, Essential Thrombocythemia, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.

Jason M. Bierenbaum
Advanced in Essential Thrombocythemia
Dr. Jason M. Bierenbaum
Hematology Oncology
Advanced in Essential Thrombocythemia
Dr. Jason M. Bierenbaum
Hematology Oncology

UPMC Hillman Cancer Center

1500 5th Avenue, 
Mckeesport, PA 
 (8.3 miles away)
412-664-2607
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Bierenbaum, MD, is a medical oncologist and hematologist at UPMC Hillman Cancer Center. Dr. Bierenbaum specializes in lung cancer, gastrointestinal cancers, and myelodysplasia. Dr. Bierenbaum is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Childhood Iron Deficiency Anemia.

James M. Rossetti
Advanced in Essential Thrombocythemia
Dr. James M. Rossetti
Hematology Oncology
Advanced in Essential Thrombocythemia
Dr. James M. Rossetti
Hematology Oncology

UPMC Hillman Cancer Center

5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
 (0.1 miles away)
412-438-2256
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James M. Rossetti, DO, is a hematologist specializing in the treatment of hematological malignancies and myeloid diseases, including myelodysplasia, acute myeloid leukemia, and myeloproliferative neoplasm. He also specializes in cellular therapy. Dr. Rossetti is a referral physician for the UPMC MDS Center of Excellence. Dr. Rossetti is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant.

VIEW MORE ESSENTIAL THROMBOCYTHEMIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sehgal's expertise for a condition
ConditionClose
  • Elite
  • Non-Hodgkin Lymphoma
    Dr. Sehgal is
    Elite
    . Learn about Non-Hodgkin Lymphoma.
    See more Non-Hodgkin Lymphoma experts
  • Distinguished
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Sehgal is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Sehgal is
    Distinguished
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • B-Cell Lymphoma
    Dr. Sehgal is
    Distinguished
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Follicular Lymphoma
    Dr. Sehgal is
    Distinguished
    . Learn about Follicular Lymphoma.
    See more Follicular Lymphoma experts
  • Advanced
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Sehgal is
    Advanced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Agranulocytosis
    Dr. Sehgal is
    Advanced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Bone Marrow Aspiration
    Dr. Sehgal is
    Advanced
    . Learn about Bone Marrow Aspiration.
    See more Bone Marrow Aspiration experts
  • Bone Marrow Transplant
    Dr. Sehgal is
    Advanced
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
  • Childhood Acute Myeloid Leukemia
    Dr. Sehgal is
    Advanced
    . Learn about Childhood Acute Myeloid Leukemia.
    See more Childhood Acute Myeloid Leukemia experts
  • Chronic B-Cell Leukemia (CBCL)
    Dr. Sehgal is
    Advanced
    . Learn about Chronic B-Cell Leukemia (CBCL).
    See more Chronic B-Cell Leukemia (CBCL) experts
View All 16 Advanced Conditions
  • Experienced
  • Acute Erythroid Leukemia (AEL)
    Dr. Sehgal is
    Experienced
    . Learn about Acute Erythroid Leukemia (AEL).
    See more Acute Erythroid Leukemia (AEL) experts
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Sehgal is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Monoblastic Leukemia (AmoL)
    Dr. Sehgal is
    Experienced
    . Learn about Acute Monoblastic Leukemia (AmoL).
    See more Acute Monoblastic Leukemia (AmoL) experts
  • Anaplastic Large Cell Lymphoma
    Dr. Sehgal is
    Experienced
    . Learn about Anaplastic Large Cell Lymphoma.
    See more Anaplastic Large Cell Lymphoma experts
  • Aplastic Anemia
    Dr. Sehgal is
    Experienced
    . Learn about Aplastic Anemia.
    See more Aplastic Anemia experts
  • Cardiac Amyloidosis
    Dr. Sehgal is
    Experienced
    . Learn about Cardiac Amyloidosis.
    See more Cardiac Amyloidosis experts
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment